Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry

OBJECTIVE: Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Viktoria, Buron, Mathias Due, Siersma, Volkert, Rasmussen, Peter Vestergaard, Illes, Zsolt, Kant, Matthias, Hilt, Claudia, Mezei, Zsolt, Roshanisefat, Homayoun, Sejbæk, Tobias, Weglewski, Arkadiusz, van Wingerden, Janneke, Geertsen, Svend Sparre, Bramow, Stephan, Sellebjerg, Finn, Magyari, Melinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130956/
https://www.ncbi.nlm.nih.gov/pubmed/34003862
http://dx.doi.org/10.1371/journal.pone.0250820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130956/
https://www.ncbi.nlm.nih.gov/pubmed/34003862
http://dx.doi.org/10.1371/journal.pone.0250820

Ejemplares similares